Ulcerative colitis nursing: pathophysiology, assessment, and care

Ulcerative colitis (UC) is a chronic, relapsing-remitting inflammatory bowel disease confined to the colon and rectum. Unlike Crohn’s disease, which can affect any segment of the GI tract transmurally, UC produces continuous mucosal inflammation that always involves the rectum and extends proximally in a predictable, uninterrupted pattern. Bloody diarrhea is its hallmark. Surgery — specifically proctocolectomy — is the only cure, making UC the one IBD where a scalpel can end the disease.

This reference covers UC pathophysiology, clinical presentation, disease severity classification, diagnostics, medical and surgical management, nursing interventions, colorectal cancer surveillance, and NCLEX decision scenarios. Use it alongside the IBD nursing overview and the Crohn’s disease nursing reference for comprehensive GI coverage.

Ulcerative colitis at a glance

Pathophysiology

Ulcerative colitis arises from a dysregulated mucosal immune response in genetically susceptible individuals. While Crohn’s disease is driven by a Th1 cytokine pattern, UC is predominantly a Th2-mediated process characterized by excess production of IL-4, IL-5, and IL-13. These cytokines activate eosinophils and mast cells, impair the intestinal epithelial barrier, and promote sustained mucosal inflammation.

The disease is confined to the epithelium and lamina propria — it does not penetrate the muscularis propria under normal circumstances. This mucosal restriction has several downstream consequences:

• Crypt abscesses: Neutrophils infiltrate the intestinal crypts of Lieberkühn, forming small pockets of purulent material within the crypt lumen. Crypt abscesses are the histological signature of active UC.
• Goblet cell depletion: The sustained inflammatory state depletes mucus-producing goblet cells, compromising the protective mucus layer and perpetuating mucosal injury.
• Pseudopolyps: Repeated cycles of ulceration and regeneration create islands of surviving mucosa surrounded by denuded areas. These “pseudopolyps” are visible on colonoscopy and are benign but can be confused with adenomatous polyps.
• Loss of haustrations: Chronic inflammation causes smooth muscle changes and foreshortening of the colon, leading to the “lead pipe” appearance on imaging — a colon without the normal haustra folds.

Inflammation always begins in the rectum and extends proximally in a continuous, uninterrupted pattern. This is a defining anatomical feature: there are no skip lesions in UC. Disease extent is classified as proctitis (rectum only), left-sided colitis (up to the splenic flexure), or pancolitis (beyond the splenic flexure to the cecum). Extent directly determines both symptom burden and long-term cancer risk.

Clinical presentation

Gastrointestinal symptoms

Bloody diarrhea is the cardinal feature of UC and the most tested distinction from Crohn’s disease on NCLEX. Patients typically report:

• Frequent loose stools mixed with bright red blood and mucus
• Tenesmus — a persistent sensation of rectal fullness and the urge to defecate, even after defecation
• Urgency — inability to delay defecation, often leading to incontinence during severe flares
• Lower abdominal cramping, often relieved temporarily after bowel movements
• Nocturnal diarrhea (diarrhea that wakes the patient from sleep is a red flag for inflammatory, rather than functional, disease)

During severe disease, stool frequency may exceed 10-15 episodes per 24 hours. Gross blood loss can be substantial.

Extraintestinal manifestations

UC drives systemic inflammation that extends beyond the gut. Key extraintestinal manifestations (EIMs) include:

• Joints: Peripheral arthritis (parallels bowel activity), sacroiliitis, and ankylosing spondylitis (activity independent of bowel disease)
• Skin: Erythema nodosum (tender, raised, red-brown nodules on the shins — correlates with bowel flares), pyoderma gangrenosum (deep, painful ulcers with violaceous borders — can occur in remission)
• Eyes: Uveitis (anterior — pain, photophobia, blurred vision), episcleritis (milder, correlates with bowel activity)
• Liver/biliary: Primary sclerosing cholangitis (PSC) — the most serious EIM in UC and discussed further below

Primary sclerosing cholangitis

PSC is the strongest extraintestinal association in ulcerative colitis. Approximately 2-7% of UC patients develop PSC, but the reverse relationship is more striking: 70-80% of all PSC patients have IBD, and UC accounts for the majority of those cases. PSC is characterized by progressive fibro-inflammatory stricturing of the intra- and extrahepatic bile ducts, leading to cholestasis, cirrhosis, and end-stage liver disease. Alkaline phosphatase and GGT are elevated out of proportion to transaminases. PSC activity does not correlate with bowel disease activity — patients may have quiescent colitis and active PSC simultaneously. Importantly, UC patients with PSC have a substantially elevated colorectal cancer risk and require annual surveillance colonoscopy from the time of PSC diagnosis.

See the cirrhosis nursing reference for management of advanced hepatic complications.

Toxic megacolon

Toxic megacolon is a life-threatening complication requiring immediate recognition. It occurs when transmural inflammation (a temporary exception in severe UC) causes neuromuscular dysfunction of the colon wall, loss of motor tone, and colonic dilatation to >6 cm (>8 cm in the transverse colon). Nursing assessment findings include:

• Abdominal distension — rapidly worsening
• Decreased or absent bowel sounds
• Fever (>38.6°C), tachycardia (>120 bpm)
• Leukocytosis with left shift
• Sudden decrease in stool frequency (misleading — the atonic colon stops passing stool, which can suggest false improvement)
• Altered mental status in severe cases

Toxic megacolon is a surgical emergency. Management includes immediate decompression (NPO, nasogastric tube), IV steroids, broad-spectrum antibiotics, and emergent surgical consultation. Colonoscopy and barium enema are contraindicated in this setting due to perforation risk.

UC vs Crohn’s disease: key distinctions

Distinguishing UC from Crohn’s disease is one of the most consistently tested topics in NCLEX GI questions.

Memory cue: Ulcerative colitis: Uniform and continuous, Upper layers only (mucosal), always involves the rectum, Uniquely curable with surgery. Crohn’s: Can occur anywhere, Cobblestone, Creeping fat, Complications (fistulas, abscesses).

Disease severity classification: Truelove-Witts criteria

The Truelove-Witts criteria (1955) remain a foundational clinical tool for classifying UC severity. They guide decisions about outpatient vs inpatient management, the need for systemic corticosteroids, and escalation to IV therapy or surgery.

Fulminant/acute severe UC meets the severe criteria plus: ≥10 bloody stools/day, continuous bleeding, abdominal distension or tenderness, fever, and often requiring transfusion. Fulminant UC warrants hospital admission, IV methylprednisolone, and urgent surgical consultation if no response within 3-5 days (the “rescue therapy” decision point: infliximab or cyclosporine vs colectomy).

Diagnostics

Colonoscopy with biopsy is the gold standard for diagnosis and for distinguishing UC from Crohn’s colitis, infectious colitis, and other causes of bloody diarrhea. Endoscopic findings in active UC include:

• Mucosal erythema, friability, and loss of the normal vascular pattern
• Granularity and contact bleeding
• Pseudopolyps in chronic disease
• Loss of haustrations (lead-pipe colon) in longstanding disease

Biopsy findings are essential for diagnosis: crypt abscesses, goblet cell depletion, basal plasmacytosis (plasma cells below the crypts — an early, specific finding), and distorted crypt architecture. The absence of granulomas distinguishes UC from Crohn’s disease.

Before starting steroids: Rule out infectious colitis — particularly Clostridioides difficile (C. diff), which can mimic or complicate UC. Send stool cultures, ova and parasite exam, and C. diff toxin assay before initiating immunosuppressive therapy. Starting steroids in unrecognized infectious colitis can be catastrophic.

Laboratory workup:

• CBC: Anemia (iron-deficiency from blood loss, normocytic from chronic disease), leukocytosis in severe flares or infection, thrombocytosis (reactive, from inflammation)
• CMP: Hypokalemia, hypoalbuminemia in severe disease; check hepatic panel (ALT, AST, alkaline phosphatase, GGT) to screen for PSC
• ESR and CRP: Markers of systemic inflammation; both elevated in moderate-severe disease
• Fecal calprotectin: Elevated intestinal inflammation marker; distinguishes IBD from IBS and monitors mucosal healing; sensitive but not specific for UC vs Crohn’s
• Stool cultures and C. diff toxin: Mandatory before starting or escalating immunosuppression

Medical management

Treatment is stratified by disease severity and extent. Goals are to induce remission, achieve mucosal healing, and maintain steroid-free remission long-term.

5-aminosalicylates (5-ASA)

Mesalamine (5-ASA) is first-line therapy for mild-to-moderate UC. Its mechanism is topical anti-inflammatory action directly on the colonic mucosa — it inhibits prostaglandin synthesis, reduces leukotriene production, and scavenges reactive oxygen species at the mucosal surface. It is minimally absorbed systemically, which limits side effects. Formulations include oral (for proximal disease) and rectal (suppositories for proctitis, enemas for left-sided disease). Patient education: the drug works locally — compliance with rectal formulations is essential even if oral therapy has been started.

Sulfasalazine is the older 5-ASA compound (5-ASA + sulfapyridine); the sulfapyridine component causes more side effects (headache, GI intolerance, male infertility). Requires folate supplementation due to folate antagonism.

Corticosteroids

Used for induction of remission in moderate-to-severe flares. Oral prednisone for outpatient moderate disease; IV methylprednisolone for hospitalized severe UC. Budesonide MMX (extended-release formulation) provides targeted colonic release with lower systemic exposure, appropriate for mild-to-moderate active disease. Corticosteroids are never used for maintenance — steroid dependence or failure triggers escalation to immunomodulators or biologics.

Nursing monitoring: hyperglycemia, blood pressure, mood changes, signs of infection, adrenal suppression with abrupt discontinuation.

Thiopurines

Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used for maintenance of remission. Slow onset (3-6 months). Check thiopurine methyltransferase (TPMT) activity before initiation — patients with low or absent TPMT cannot metabolize thiopurines and are at risk for severe, potentially fatal myelosuppression. Monitor CBC and LFTs regularly (weekly for the first month, then every 3 months). Report leukopenia, thrombocytopenia, or abnormal liver enzymes immediately.

Biologics

Anti-TNF agents — infliximab and adalimumab: First-line biologics for moderate-to-severe UC. Screen for latent TB and hepatitis B before initiating. Infliximab (IV infusion) also serves as rescue therapy in hospitalized patients with acute severe UC who have failed IV steroids.

Vedolizumab: A gut-selective anti-integrin biologic that blocks the α4β7 integrin on lymphocytes, preventing their trafficking to the GI mucosa via MAdCAM-1. Because this integrin is specifically expressed in gut and liver vasculature (rather than throughout the body), vedolizumab has a favorable systemic safety profile. It does not suppress systemic immune surveillance the way anti-TNF agents do, making it an attractive choice for patients at higher infection risk or those who have failed anti-TNF therapy. Vedolizumab is preferred in UC over Crohn’s disease because the α4β7/MAdCAM-1 pathway is more central to colonic inflammation than small bowel inflammation.

Ustekinumab: Anti-IL-12/23 monoclonal antibody; effective for moderate-to-severe UC, particularly after anti-TNF failure or intolerance.

JAK inhibitors

Tofacitinib is an oral JAK inhibitor approved for moderate-to-severe UC. It provides rapid onset of action (faster than biologics). Monitoring requirements: monitor for infections (including herpes zoster reactivation — live zoster vaccine should be given before starting if possible), lipid panel (can cause hyperlipidemia), CBC, and DVT/PE risk (a black box warning exists for thrombosis). JAK inhibitors are generally used in patients who have failed or cannot tolerate biologics.

Nursing assessment

Bowel pattern monitoring

Document stool frequency, consistency, and blood volume with each episode. During acute flares, a stool diary tracks disease severity and medication response. Note any decrease in frequency that may paradoxically indicate toxic megacolon (atonic colon stops passing stool).

Fluid and electrolyte status

Frequent bloody diarrhea depletes sodium, potassium, magnesium, and bicarbonate. Assess for dehydration (tachycardia, dry mucous membranes, decreased skin turgor, concentrated urine, orthostatic hypotension). Review BMP, especially potassium and bicarbonate. Monitor strict intake and output.

Nutritional assessment

Weigh patients daily during hospitalization. Review albumin and prealbumin as markers of nutritional status and disease severity. Low albumin is associated with worse outcomes and delayed wound healing post-surgery. During severe flares, nutritional intake is often severely restricted due to pain, nausea, and NPO status during diagnostic workup.

Pain assessment

Assess location, quality, and severity of abdominal pain. Use a validated pain scale and document response to analgesia. Cramping that improves after bowel movements is typical of active colitis. Rebound tenderness, guarding, or rigidity suggest peritoneal involvement and mandate immediate provider notification — perforation and toxic megacolon are emergencies.

Skin integrity

Assess perianal skin for excoriation, skin breakdown, and moisture-associated dermatitis from frequent liquid stools. Inspect for pyoderma gangrenosum (deep ulcerations with violaceous borders), which can occur anywhere on the body and requires wound management and often systemic therapy.

Psychosocial assessment

UC substantially impairs quality of life. Screen for anxiety and depression — prevalence is high in IBD. Assess the impact of urgency and fecal incontinence on daily functioning, work, and relationships. For patients facing surgery, assess readiness for stoma education and emotional response to potential body image changes.

Nursing interventions

• Administer medications as scheduled: 5-ASA rectal formulations must be used consistently — patient education on technique and importance of compliance with rectal therapy reduces relapse rates
• IV fluid and electrolyte replacement: During moderate-to-severe flares; correct hypokalemia before it precipitates cardiac arrhythmias
• Nutritional support: Collaborate with dietitian; enteral nutrition (EN) preferred over parenteral if gut is functional; small, frequent meals during remission
• Perianal skin care: Barrier cream (zinc oxide, petrolatum) after each bowel movement; gentle cleansing with pH-balanced products; avoid vigorous wiping
• Infection surveillance: Monitor temperature, WBC, and clinical signs — distinguish disease flare from superimposed infection. C. diff is a particular hazard in immunosuppressed UC patients
• Pre-surgical education: For patients going to colectomy, begin stoma education early; involve wound, ostomy, and continence (WOC) nurse; mark stoma site preoperatively with input from the patient
• Patient education: Signs of flare, medication adherence, avoiding NSAID use (can precipitate UC flares), and when to seek emergency care (high fever, abdominal distension, rapidly increasing pain)

Surgical considerations

UC is the only form of IBD that is potentially cured by surgery. Total proctocolectomy removes all disease-bearing tissue (the entire colon and rectum), eliminating the risk of colorectal cancer and ending the inflammatory cycle.

Indications for surgery

• Medically refractory disease (failure of biologic therapy and immunomodulators)
• Acute severe UC that fails to respond to IV steroids and rescue therapy within 3-7 days (fulminant colitis)
• Toxic megacolon
• Dysplasia or colorectal cancer found on surveillance colonoscopy
• Intolerable medication side effects

Restorative proctocolectomy with IPAA (J-pouch)

The preferred procedure for most patients is restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) — commonly called the J-pouch procedure. The terminal ileum is fashioned into a J-shaped reservoir that is anastomosed to the anal canal, preserving fecal continence. Most patients achieve 4-8 formed or semi-formed stools per day.

The procedure is typically performed in two stages (proctocolectomy + diverting loop ileostomy, then ileostomy closure) or three stages in higher-risk patients (subtotal colectomy first to stabilize the patient, then completion proctectomy with pouch creation, then ileostomy closure).

Nursing care post-IPAA:

• Diverting ileostomy care: stoma site assessment, pouching system management, output monitoring (500-1,000 mL/day typical; high-output ileostomy >1,500 mL/day warrants fluid and electrolyte management)
• After ileostomy closure and J-pouch activation: teach pelvic floor exercises, bowel diary, skin protection
• Signs of anastomotic leak: fever, tachycardia, increasing abdominal pain 3-5 days post-op

Pouchitis

Pouchitis is the most common long-term complication after IPAA, occurring in approximately 20% of patients at 1 year and up to 50% cumulatively over 10 years. It is inflammation of the ileal pouch reservoir. Presentation includes increased stool frequency (above the patient’s established baseline), bloody stool, urgency, cramping, and systemic symptoms in severe cases. First-line treatment is a 2-week course of metronidazole or ciprofloxacin. Chronic antibiotic-dependent or refractory pouchitis may require biologics or, rarely, pouch excision.

Nursing assessment for pouchitis: Compare current stool frequency and character to the patient’s established post-IPAA baseline. Distinguish pouchitis from other post-IPAA complications (cuffitis, Crohn’s disease of the pouch, irritable pouch syndrome).

Colorectal cancer risk and surveillance

UC pancolitis is a significant risk factor for colorectal cancer (CRC). The mechanism is dysplasia arising from chronically inflamed, regenerating colonic epithelium — distinct from the adenoma-to-carcinoma sequence of sporadic CRC.

Risk stratification:

• Proctitis only: no elevated CRC risk
• Left-sided colitis: moderately elevated risk; surveillance begins after 10 years of disease
• Pancolitis: highest risk; surveillance colonoscopy begins after 8 years of disease
• UC with concurrent PSC: annual surveillance colonoscopy from time of PSC diagnosis (regardless of disease duration or extent)

Surveillance intervals:

• Low risk (inactive disease, no dysplasia, no family history of CRC): every 3 years
• Intermediate risk (mild active disease, pseudopolyps, family history of CRC): every 2 years
• High risk (dysplasia detected on prior surveillance, strictures, active disease, PSC): every year

Chemoprevention: Long-term 5-ASA therapy is associated with a modest reduction in CRC risk in UC. Folate supplementation also reduces CRC risk and is particularly important for patients on sulfasalazine (which antagonizes folate absorption). Encourage adequate folate intake in all UC patients.

Nursing education: Explain the surveillance schedule to patients during remission, not only during flares. Regular colonoscopy compliance is a nursing teaching priority for any UC patient with 8+ years of pancolitis.

NCLEX decision scenarios

Scenario 1

A nurse is caring for a patient hospitalized with a severe UC flare who was started on IV methylprednisolone 48 hours ago. The patient reports that stool frequency has decreased from 14 to 2 episodes in the past 12 hours. The abdomen appears distended and the patient seems less distressed. Which action is the nurse’s priority?

A. Document the improvement and continue the current plan B. Notify the provider — decreased stool frequency with distension may indicate toxic megacolon C. Advance the patient’s diet as tolerated given the clinical improvement D. Reduce IV fluid rate now that diarrhea has decreased

Correct answer: B. A sudden decrease in stool frequency in a patient with severe UC is a red flag — when the colon becomes atonic in toxic megacolon, it stops passing stool, creating a false impression of improvement. Abdominal distension in this context should prompt immediate provider notification and abdominal imaging.

Scenario 2

A 35-year-old patient with mild UC is starting mesalamine (5-ASA) therapy. Which statement by the patient about the rectal suppository formulation requires correction?

A. “I should use this every night before bed.” B. “I can stop using the suppository once my bleeding resolves.” C. “This medication works directly on the lining of my rectum.” D. “I might need to use this long-term to keep the disease in remission.”

Correct answer: B. Stopping 5-ASA when symptoms resolve leads to relapse. Mesalamine is a maintenance therapy — its topical anti-inflammatory mechanism works continuously at the mucosal surface to prevent recurrence. Patients must understand that feeling better is a goal of therapy, not a signal to stop.

Scenario 3

A patient with long-standing UC has elevated alkaline phosphatase and GGT on routine labs. Bilirubin and transaminases are mildly elevated. The patient reports occasional right upper quadrant ache and fatigue. Which condition should the nurse recognize as a likely diagnosis?

A. Acute hepatitis from azathioprine hepatotoxicity B. Gallstones from rapid weight loss during flares C. Primary sclerosing cholangitis (PSC) D. Hepatorenal syndrome from severe hypoalbuminemia

Correct answer: C. PSC is the most common hepatobiliary extraintestinal manifestation of UC, affecting 2-7% of patients. It produces progressive bile duct stricturing with a cholestatic pattern — elevated alkaline phosphatase and GGT, with milder transaminase elevation. This patient now requires annual surveillance colonoscopy regardless of disease duration. See the cirrhosis nursing reference and hepatic encephalopathy content for liver disease progression management.

Scenario 4

A patient with severe UC is admitted and placed on IV corticosteroids. Before starting therapy, which action is the nurse’s priority?

A. Verify that a tuberculosis skin test has been placed B. Obtain stool cultures and send C. diff toxin assay C. Obtain a baseline echocardiogram D. Confirm that the patient has had a recent colonoscopy

Correct answer: B. Infectious colitis — particularly C. difficile — can mimic UC or complicate it. Starting corticosteroids without ruling out infection can worsen infectious colitis significantly. Stool cultures, ova and parasite exam, and C. diff toxin must be sent before immunosuppression is initiated. TB screening is required before biologics, not corticosteroids.

Scenario 5

A patient with UC is starting vedolizumab after failing infliximab. The patient asks why the gastroenterologist chose this drug over another anti-TNF agent. The most accurate nursing response is:

A. “Vedolizumab works in the bowel specifically, which may cause fewer systemic side effects than anti-TNF agents.” B. “It’s only used when insurance won’t cover other biologics.” C. “Vedolizumab works faster than anti-TNF agents for most people.” D. “It prevents the liver from making TNF, which reduces bowel inflammation.”

Correct answer: A. Vedolizumab’s α4β7 mechanism restricts its action to the GI mucosa (and to a lesser extent, the liver), producing less systemic immunosuppression than anti-TNF agents. This makes it particularly favorable for patients at increased infection risk. It does not act faster than anti-TNF agents — onset is generally slower.

Scenario 6

Three weeks after restorative proctocolectomy with IPAA for UC, a patient reports 8-10 loose stools per day (up from 5-6 per day recently), urgency, cramping, and streaks of blood in stool. The nurse should anticipate an order for:

A. Repeat CT scan to evaluate for anastomotic leak B. Stool culture for C. diff and a course of antibiotics for pouchitis C. Colonoscopy to rule out Crohn’s disease of the new pouch D. Prednisone for recurrent UC activity

Correct answer: B. Pouchitis — the most common long-term complication after IPAA — presents with increased stool frequency above baseline, urgency, cramping, and blood. First-line treatment is metronidazole or ciprofloxacin. Stool culture rules out concurrent infection. UC cannot recur in the pouch (the colon has been removed), but Crohn’s disease of the pouch is a separate, longer-term concern.

Scenario 7

A patient with 12 years of UC pancolitis asks why they need a surveillance colonoscopy every 2-3 years if they feel completely well and their last scope was normal. Which explanation is most accurate?

A. Surveillance is required by law for all IBD patients. B. Chronic colitis increases the risk of colorectal cancer even during remission, and dysplasia may not cause symptoms until advanced. C. The colonoscopy will confirm that the UC has resolved since inflammation is no longer present. D. Surveillance colonoscopies replace the need for fecal calprotectin testing in UC patients.

Correct answer: B. Dysplasia in UC-associated CRC often develops in flat mucosa without polyp formation, making it invisible without mucosal biopsies. Patients with pancolitis for >8-10 years have significantly elevated CRC risk even in clinical remission, because ongoing subclinical epithelial injury and regeneration drive dysplasia. Surveillance colonoscopy is not a treatment compliance check — it is cancer prevention.

Key takeaways

• UC is a mucosal, continuous, rectum-first inflammatory bowel disease confined to the colon — bloody diarrhea and tenesmus are cardinal features
• Toxic megacolon is a life-threatening emergency: paradoxical decrease in stool frequency, abdominal distension, and fever in a severe UC patient should prompt immediate provider notification
• Unlike Crohn’s disease, UC is potentially cured by proctocolectomy — the J-pouch (IPAA) procedure preserves continence in most patients
• Pouchitis affects up to 50% of IPAA patients over time — first-line treatment is metronidazole or ciprofloxacin
• PSC is the most important hepatobiliary EIM of UC; it mandates annual surveillance colonoscopy from diagnosis
• Vedolizumab is the gut-selective biologic — its α4β7/MAdCAM-1 mechanism confines immunosuppression to the GI tract, reducing systemic infection risk
• Pancolitis confers significant CRC risk after 8 years; surveillance colonoscopy schedule and chemoprevention (5-ASA, folate) are nursing teaching priorities
• Always rule out infectious colitis (C. diff, stool cultures) before initiating or escalating immunosuppressive therapy

For GI bleed management when UC-related hemorrhage occurs, see the GI bleed nursing reference. For the broader IBD framework, see the IBD nursing overview.